Return on Assets (ROA): Vertex's financial strength is reflected in its exceptional ROA, which exceeds industry averages.

Vertex should earn other important approvals through 2030 that could jolt its stock price. It's developing a treatment called ...

Vertex Pharmaceuticals Incorporated remains a leader in CF treatments, fueling robust cash flow and pipeline expansions.

Vertex Pharmaceuticals is offering Enlaza Therapeutics more than $2 billion in biobucks through a multitarget drug discovery deal aiming to create new T-cell engagers and small-format drug conjugates.

Vertex (VERX) shares have come under pressure in recent trading. The stock has seen losses of 7% over the past day and nearly 10% for the week. This has sparked questions about what might be driving ...

Jupiter Endovascular, which was formed by Neptune Medical a little more than a year ago, shared positive results from the ...